Drug intelligence / Profile preview

NUMARZU-001

Development stage: Phase 2
Lead developer: SOLTI
Modality: Cell Therapies
Administration: Intravenous

Overview

NUMARZU-001 is an autologous adoptive cell therapy consisting of PD-1-selected tumor-infiltrating lymphocytes (TILs). Developed by the Fundació Clínic per a la Recerca Biomèdica (Hospital Clínic de Barcelona), the therapy involves isolating TILs from a patient's tumor, selecting for the PD-1 positive (PD1+) population—which is enriched for tumor-reactive T cells—and expanding them ex vivo before re-infusion. This approach aims to enhance the anti-tumor immune response in patients with advanced or metastatic triple-negative breast cancer (TNBC), potentially overcoming the limitations of unselected TIL populations.

Brand names: NUMARZU-001NUMARZU001NUMARZU 001
Other names: PD1+ Tumor-infiltrating Lymphocytes

Targets

TAA-HLA-A*02 (Tumor-associated antigen peptide-HLA-A*02 complex)

Beyond the preview

Go deeper on NUMARZU-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NUMARZU-001.

Explore the full profile